International Journal of Vasculitis - Call for Papers
Advancing vasculitis science through open access publishing
Call for Papers Quick View
- Scope: vasculitis and vascular inflammation
- Article types: research, reviews, brief reports
- Ethics approvals required when applicable
- Data availability statement required
- Use clinical reporting guidelines
- Two submission routes available
- Open access visibility and global reach
- Rapid editorial screening for scope fit
Priority Topics and Scope
International Journal of Vasculitis invites submissions that advance understanding of vascular inflammatory disorders across clinical, translational, and population health domains.
We welcome research on large, medium, and small vessel vasculitis, including giant cell arteritis, Takayasu arteritis, ANCA-associated vasculitis, polyarteritis nodosa, and IgA vasculitis.
Priority topics include diagnosis, imaging, biomarkers, immunopathogenesis, epidemiology, and therapeutic outcomes.
We value rigorous clinical trials, observational cohorts, registry analyses, and mechanistic studies linked to patient outcomes.
Studies on biologic therapies, steroid-sparing strategies, relapse prevention, and long term disease monitoring are encouraged.
All submissions must include clear ethics approvals, data availability, and trial registration when applicable.
We welcome submissions on vasculitis imaging, PET-CT, MR angiography, and ultrasound diagnostics.
Studies on ANCA subtypes, cytokine profiling, and biomarker validation are within scope.
Research on steroid sparing strategies and biologic therapies is encouraged.
Population studies on incidence, relapse, and outcomes are welcome.
Pediatric vasculitis and transition care studies are encouraged.
Systematic reviews and meta analyses should follow PRISMA guidance.
Real world evidence and registry studies are encouraged.
Studies on vasculitis relapse prediction, flare monitoring, and remission maintenance are encouraged.
We welcome research on vascular imaging protocols and standardized scoring systems.
Mechanistic studies on immune pathways and endothelial injury are in scope.
Clinical trials and comparative effectiveness studies of biologics are prioritized.
Research on patient reported outcomes and quality of life is encouraged.
Guideline implementation and care pathway studies are welcome.
Studies on comorbidity management and infection risk are relevant.
Submissions should clearly report diagnostic criteria and classification frameworks.
We invite translational studies linking immune profiling with clinical phenotypes and treatment response.
Submissions on vasculitis complications such as aneurysm formation, thrombosis, and organ ischemia are welcome.
We encourage multidisciplinary work bridging rheumatology, nephrology, pulmonology, and vascular surgery.
Health services research on care pathways, referral delays, and outcomes disparities is within scope.
Brief communications reporting novel biomarkers or therapeutic signals are considered when clinically relevant.
Case series should emphasize diagnostic insights, therapeutic lessons, and clear follow up documentation.
We welcome work on long term outcomes after induction therapy and maintenance strategies.
Quality improvement studies evaluating guideline adherence in vasculitis care are encouraged.
We also invite policy perspectives on vasculitis care delivery and access to advanced therapies.
Manuscripts addressing diagnostic delay or health equity in vasculitis care are encouraged.
Implementation studies that translate guidelines into clinical practice are welcome.
We encourage methodological innovations in imaging, pathology, and bioinformatics for vasculitis.
Interdisciplinary work linking cardiology, nephrology, and rheumatology is in scope.
Why Publish with IJV
Specialist Review
Peer review by rheumatologists, immunologists, and vascular medicine experts.
Open Access Reach
Immediate access improves visibility among clinicians and researchers.
Rapid Decisions
Clear workflows reduce delays and support timely dissemination.
Metadata Quality
Structured metadata improves indexing and citation tracking.
Submission Categories
Original Research
PrimaryFull length studies presenting new findings in vasculitis and vascular medicine.
- Clinical, translational, or outcomes research
- Clear study design and statistical reporting
- Defined populations and endpoints
- Data availability statements required
Review Articles
SynthesisComprehensive reviews summarizing evidence and guiding clinical practice.
- Systematic or narrative reviews
- PRISMA aligned search strategies
- Consensus building across the field
- High impact topics prioritized
Brief Reports
ConciseShorter manuscripts reporting rapid findings or preliminary data with clear value.
- Focused clinical or laboratory findings
- Strong reproducibility signals
- Rapid publication workflows
- Appropriate for timely data
Scope Fit
Prioritize manuscripts that advance vasculitis diagnosis, treatment, or mechanistic insight.
Ethics and Data
Include ethics approvals, consent statements, and data availability at submission.
Submission Routes
Submit via ManuscriptZone or the simple submission form to match your workflow.
Submission Pathway
Confirm Scope
Ensure the manuscript aligns with vasculitis and vascular inflammation priorities.
Prepare Files
Follow author guidelines for formatting, ethics approvals, and data availability.
Submit Online
Submit via ManuscriptZone or the simple submission form for editorial screening.
Vasculitis Topics We Publish
Call for Papers FAQs
Do you accept interdisciplinary research?
Yes. Studies bridging immunology, nephrology, and vascular medicine are welcome.
Are real-world evidence studies considered?
Yes. Well designed registry or observational studies are encouraged.
How fast are decisions?
We prioritize efficient review with timely editorial decisions.
Are case reports accepted?
Yes. High-quality case reports on rare vasculitides are welcome.
Submit Your Manuscript
Use the submission portals above to share vasculitis research with a global audience.
Need help? Contact us at [email protected]
